Keyphrases
Systemic Lupus Erythematosus
100%
Cancer Risk
100%
Medication Exposure
100%
Case-cohort Study
100%
Immunosuppressive Drugs
60%
Immunosuppressive Therapy
40%
Adjusted Hazard Ratio
40%
Cancer Cases
40%
Race-ethnicity
20%
Lung Cancer
20%
Risk Factors
20%
Hematological Malignancies
20%
Hazard Ratio
20%
Methotrexate
20%
Aspirin
20%
Disease Activity
20%
Cyclophosphamide
20%
Hematological Cancer
20%
Systemic Glucocorticoids
20%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
20%
Risk of Malignancy
20%
Damage Grade
20%
Drug Exposure
20%
Tumor Registry
20%
Sample Age
20%
Tobacco Exposure
20%
Lupus Damage
20%
Antimalarial Drugs
20%
Non-malignancy
20%
Medicine and Dentistry
Drug Therapy
100%
Malignant Neoplasm
100%
Cohort Analysis
100%
Systemic Lupus Erythematosus
100%
Cancer Risk
100%
Hazard Ratio
60%
Immunosuppressive Drug
60%
Immunosuppressive Treatment
40%
Cancer
40%
Lupus Erythematosus
20%
Neoplasm
20%
Hematologic Malignancy
20%
Methotrexate
20%
Glucocorticoid
20%
Disease Activity
20%
Cyclophosphamide
20%
Hematological Cancer
20%
Lung Cancer
20%
Azathioprine
20%
Acetylsalicylic Acid
20%
Nonsteroid Antiinflammatory Agent
20%
Drug Exposure
20%
Antimalarial Agent
20%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Malignant Neoplasm
100%
Systemic Lupus Erythematosus
100%
Immunosuppressive Agent
83%
Lung Cancer
16%
Neoplasm
16%
Methotrexate
16%
Glucocorticoid
16%
Disease Activity
16%
Cyclophosphamide
16%
Acetylsalicylic Acid
16%
Non-Steroidal Anti-Inflammatory Drug
16%
Hematologic Malignancy
16%
Azathioprine
16%
Antimalarial Agent
16%
Immunology and Microbiology
Systemic Lupus Erythematosus
100%
Immunosuppressive Drug
60%
Immunosuppressive Therapy
40%
Glucocorticoid
20%
Cyclophosphamide
20%
Lupus Erythematosus
20%
Methotrexate
20%
Azathioprine
20%
Drug Exposure
20%
Antimalarial Agent
20%